Gallo Giovanna, Nalli Gabriele, Baratta Francesco, Desideri Giovambattista, Savoia Carmine
Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
Geriatric Unit, Department of Internal Medicine and Medical Specialties, AOU Policlinico Umberto I, 00161 Rome, Italy.
Int J Mol Sci. 2025 Aug 21;26(16):8081. doi: 10.3390/ijms26168081.
Metabolic dysfunction-associated steatotic liver disease (MASLD) significantly increases the risk of steatohepatitis and cirrhosis and multiple extrahepatic complications, in particular, cardiometabolic disease, including type 2 diabetes, atherosclerotic cardiovascular disease (CVD), and heart failure, with a significant negative impact on health-related quality of life, becoming a substantial economic burden. Moreover, cardiovascular events represent the leading cause of death in MASLD patients. A timely diagnosis stratifies patient for their risk. It can facilitate early lifestyle changes or pharmacological management of dysmetabolic conditions, thereby slowing disease progression, lowering cardiovascular risk, and preventing CVD and cirrhosis. In this narrative review, we will discuss the current knowledge on MASLD and metabolic dysfunction-associated steatohepatitis (MASH) pathophysiology, emphasizing their systemic nature, the link to CVD, and available and emerging treatment strategies.
代谢功能障碍相关脂肪性肝病（MASLD）显著增加了脂肪性肝炎、肝硬化以及多种肝外并发症的风险，尤其是心脏代谢疾病，包括2型糖尿病、动脉粥样硬化性心血管疾病（CVD）和心力衰竭，对健康相关生活质量产生重大负面影响，成为巨大的经济负担。此外，心血管事件是MASLD患者的主要死因。及时诊断可对患者的风险进行分层。这有助于早期改变生活方式或对代谢异常状况进行药物管理，从而减缓疾病进展、降低心血管风险并预防CVD和肝硬化。在这篇叙述性综述中，我们将讨论关于MASLD和代谢功能障碍相关脂肪性肝炎（MASH）病理生理学的当前知识，强调它们的全身性、与CVD的联系以及现有的和新出现的治疗策略。
Zotero 插件